Self-assembled HCV core virus-like particles targeted and inhibited tumor cell migration and invasion

Nanoscale Research Letters

Volumn 8, Issue 1, 2013, Pages 1-10

  Li, Xiang ^a   Xu, Xuehe ^a   Jin, Aihui ^a   Jia, Qunying ^a   Zhou, Huaibin ^a   Kang, Shuai ^a   Lou, Yongliang ^a   Gao, Jimin ^a   Lu, Jianxin ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

HCV core; Invasion; Migration; Tumor specificity; Virus like particles; VLPS

Indexed keywords

CELLS; CYTOLOGY; NANOPARTICLES; PEPTIDES; TUMORS; VIRUSES;

HCV CORE; INVASION; MIGRATION; VIRUS-LIKE PARTICLES; VLPS;

TARGETED DRUG DELIVERY;

HEPATITIS C VIRUS;

EID: 84887273961     PISSN: 19317573     EISSN: 1556276X     Source Type: Journal    
DOI: 10.1186/1556-276X-8-401     Document Type: Article

References (34)

1. Bagul M, Kakumanu S, Wilson T, Nicolosi R: In vitro evaluation of antiproliferative effects of self-assembling nanoemulsion of paclitaxel on various cancer cell lines. Nano Biomed Eng 2010, 147(927):258-267.
2. Isaacs A, Lindenmann J: Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957, 147(927):258-267.
3. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, Levin M, Relman DA: Dissecting interferon-induced transcriptional programs in human peripheral blood cells. PLoS One 2010, 5(3):e9753.
4. Hynes RO: Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69(1):11-25.
5. Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, De-Pereda JM, Ginsberg MH, Calderwood DA: Talin binding to integrin beta tails: a final common step in integrin activation. Science 2003, 302(5642):103-106.
6. Ye F, Kim C, Ginsberg MH: Molecular mechanism of inside-out integrin regulation. J Thromb Haemost 2011, 9(Suppl 1):20-25.
7. Galvez BG, Matias-Roman S, Yanez-Mo M, Sanchez-Madrid F, Arroyo AG: ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J Cell Biol 2002, 159(3):509-521.
8. Ying-ying J, Hai-li Q, Meng T, Zhou-she Z, Hong-li L, Jun X, Li-sheng Z, Chen L: Comparison of combination specification of the different tumor cell with RGD peptide. J China Clin Med Imaging 2008, 19(1):35-37.
9. Mittelbronn M, Warth A, Meyermann R, Goodman S, Weller M: Expression of integrins alphavbeta3 and alphavbeta5 and their ligands in primary and secondary central nervous system neoplasms. Histol Histopathol 2013, 28(6):749-758.
10. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79(7):1157-1164.
11. Ng QK, Sutton MK, Soonsawad P, Xing L, Cheng H, Segura T: Engineering clustered ligand binding into nonviral vectors: alphavbeta3 targeting as an example. Mol Ther 2009, 17(5):828-836.
12. Guzzetti I, Civera M, Vasile F, Araldi EM, Belvisi L, Gennari C, Potenza D, Fanelli R, Piarulli U: Determination of the binding epitope of RGD-peptidomimetics to alphavbeta3 and alpha(IIb)beta3 integrin-rich intact cells by NMR and computational studies. Org Biomol Chem 2013, 11(23):3886-3893.
13. Jain KK: Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract 2008, 17(2):89-101.
14. Song H, Cao XF, Ruan J, Peng X, Wang J, Wang C, Bao CC: Application of rotatable central composite design in the preparation and optimization of poly (lactic-co-glycolic acid) nanoparticles for controlled delivery of HSA. Nano Biomed Eng 2011, 147(927):258-267.
15. Yu D, Amano C, Fukuda T, Yamada T, Kuroda S, Tanizawa K, Kondo A, Ueda M, Yamada H, Tada H, Seno M: The specific delivery of proteins to human liver cells by engineered bio-nanocapsules. FEBS J 2005, 272(14):3651-3660.
16. Shishido T, Muraoka M, Ueda M, Seno M, Tanizawa K, Kuroda S, Fukuda H, Kondo A: Secretory production system of bionanocapsules using a stably transfected insect cell line. Appl Microbiol Biotechnol 2006, 73(3):505-511.
17. Chen LS, Wang M, Ou WC, Fung CY, Chen PL, Chang CF, Huang WS, Wang JY, Lin PY, Chang D: Efficient gene transfer using the human JC virus-like particle that inhibits human colon adenocarcinoma growth in a nude mouse model. Gene Ther 2010, 17(8):1033-1041.
18. Wu Z, Li X, Sunkara M, Spearman H, Morris AJ, Huang C: PIPKIgamma regulates focal adhesion dynamics and colon cancer cell invasion. PLoS One 2011, 6(9):e24775.
19. Sidky YA, Borden EC: Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987, 47(19):5155-5161.
20. Frassoldati A, Lamparelli T, Federico M, Annino L, Capnist G, Pagnucco G, Dini E, Resegotti L, Damasio EE, Silingardi V: Hairy cell leukemia: a clinical review based on 725 cases of the Italian cooperative group (ICGHCL). Italian cooperative group for hairy cell leukemia. Leuk Lymphoma 1994, 13(3-4):307-316.
21. Hernberg M, Pyrhonen S, Muhonen T: Regimens with or without interferon-alpha as treatment for metastatic melanoma and renal cell carcinoma: an overview of randomized trials. J Immunother 1999, 22(2):145-154.
22. Zeltins A: Construction and characterization of virus-like particles: a review. Mol Biotechnol 2013, 53(1):92-107.
23. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM: Structural biology of hepatitis C virus. Hepatology 2004, 39(1):5-19.
24. Bartenschlager R, Lohmann V: Replication of hepatitis C virus. J Gen Virol 2000, 81(Pt 7):1631-1648.
25. Murray CL, Jones CT, Rice CM: Architects of assembly: roles of flaviviridae non-structural proteins in virion morphogenesis. Nat Rev Microbiol 2008, 6(9):699-708.
26. Friebe P, Boudet J, Simorre JP, Bartenschlager R: Kissing-loop interaction in the 3' end of the hepatitis C virus genome essential for RNA replication. J Virol 2005, 79(1):380-392.
27. Friebe P, Lohmann V, Krieger N, Bartenschlager R: Sequences in the 5' nontranslated region of hepatitis C virus required for RNA replication. J Virol 2001, 75(24):12047-12057.
28. Honda M, Beard MR, Ping LH, Lemon SM: A phylogenetically conserved stem-loop structure at the 5' border of the internal ribosome entry site of hepatitis C virus is required for cap-independent viral translation. J Virol 1999, 73(2):1165-1174.
29. Falcon V, Acosta-Rivero N, Chinea G, Gavilondo J, de la-Rosa MC, Menendez I, Duenas-Carrera S, Vina A, Garcia W, Gra B, Noa M, Reytor E, Barceló MT, Alvarez F, Morales-Grillo J: Ultrastructural evidences of HCV infection in hepatocytes of chronically HCV-infected patients. Biochem Biophys Res Commun 2003, 305(4):1085-1090.
30. Chua BY, Johnson D, Tan A, Earnest-Silveira L, Sekiya T, Chin R, Torresi J, Jackson DC: Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS One 2012, 7(10):e47492.
31. Liu F, Wu X, Li L, Liu Z, Wang Z: Use of baculovirus expression system for generation of virus-like particles: successes and challenges. Protein Expr Purif 2013, 90(2):104-116.
32. Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM: Development of influenza H7N9 virus like particle (VLP) vaccine: homologous a/anhui/1/2013 (H7N9) protection and heterologous a/chicken/jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 2013, 31(40):4305-4313.
33. Petry H, Goldmann C, Ast O, Luke W: The use of virus-like particles for gene transfer. Curr Opin Mol Ther 2003, 5(5):524-528.
34. Garcea RL, Gissmann L: Virus-like particles as vaccines and vessels for the delivery of small molecules. Curr Opin Biotechnol 2004, 15(6):513-517.